Target INR for Mechanical Mitral Valve Replacement
For patients with a mechanical mitral valve replacement, target an INR of 3.0 (range 2.5-3.5) with vitamin K antagonist therapy.
Guideline Recommendation
The 2020 ACC/AHA Valvular Heart Disease Guidelines provide clear direction on this matter 1. The guidelines explicitly state that mechanical mitral valves carry a higher thromboembolism risk compared to aortic mechanical valves, and patients achieve better outcomes with higher INR targets.
Key Evidence Supporting This Target:
The GELIA study demonstrated that patients with mechanical mitral prostheses maintained at a lower INR range (2.0-3.5) had worse survival rates compared to those with a higher target INR range (2.5-4.5) 1
The guideline explicitly recommends INR goal of 3.0 (range 2.5-3.5) as providing the optimal balance between preventing thromboembolism and minimizing bleeding risk in mechanical mitral valve patients 1
This recommendation appears as a Class 1 indication in the guideline's algorithm for antithrombotic therapy 1
Important Practical Considerations:
Patient Compliance Reality:
The guidelines acknowledge a critical compliance challenge: patients with a target INR of 3.0-4.5 were only within range 44.5% of the time, compared to 74.5% for those targeting 2.0-3.5 1. This is why the recommended range of 2.5-3.5 (targeting 3.0) represents a pragmatic compromise.
Recent Trial Data:
The 2023 PROACT Mitral trial attempted to validate lower-dose warfarin (INR 2.0-2.5) for On-X mechanical mitral valves but failed to demonstrate noninferiority compared to standard dosing (INR 2.5-3.5) 2. This reinforces that even with newer-generation valves, lower INR targets are not safe for mitral position valves.
Adjunctive Therapy:
If antiplatelet therapy is indicated for other reasons (e.g., coronary artery disease), add aspirin 75-100 mg daily 1. However, this is a Class 2b recommendation and should be weighed against increased bleeding risk.
Common Pitfalls to Avoid:
Do not use aortic valve INR targets (2.0-3.0) for mitral valves - this is associated with increased thromboembolism and worse survival 1
Do not assume newer-generation valves allow lower targets in the mitral position - the PROACT trial proved this assumption wrong 2
Do not target INR >3.5 routinely - this increases bleeding risk without additional thromboembolic protection 1
When to Consider Higher Targets:
Maintain INR at the upper end of the range (closer to 3.5) or consider even higher targets if additional thromboembolic risk factors are present:
- Atrial fibrillation
- Previous thromboembolism
- Hypercoagulable state
- Severe left ventricular dysfunction
- Older-generation prosthesis (e.g., ball-in-cage) 1